Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 30:2022:2417351.
doi: 10.1155/2022/2417351. eCollection 2022.

Identification and Validation of Inflammatory Response-Related Gene Signatures to Predict the Prognosis of Neuroblastoma

Jiye Song  1   2   3 , Liang Song  1 , Zhenmei Lv  1 , Jianke Liu  1 , Xuan Feng  1 , Song Zhang  1 , Aiqin Song  1
Affiliations

Identification and Validation of Inflammatory Response-Related Gene Signatures to Predict the Prognosis of Neuroblastoma

Jiye Song et al. Int J Genomics. .

Abstract

Background: Neuroblastoma (NB) is the third most common malignant tumor in children. The inflammation is believed to be closely related to NB patients' prognosis. However, there is no comprehensive research to study the role of inflammatory response-related gene (IRRG) in NB patients.

Methods: We downloaded the gene expression profiles of NB patients from GEO and TARGET database, and the expression of 200 IRRGs was extracted. Then, we performed differentially analysis between INSS stage 4 and INSS stage 4S NB patients. The univariate and multivariate Cox regression analyses were performed to screen out the overall survival- (OS-) and event-free survival- (EFS-) related IRRGs in GSE49710, and two signatures were constructed; both signatures were evaluated by Kaplan-Meier (K-M) survival curve and receiver operating characteristic (ROC) curve. Finally, the TARGET cohort was used to validate IRRG signatures, and the independence of the prognostic IRRG signatures was evaluated by integrating clinical information.

Results: We screened out 10 OS-related IRRGs and 11 EFS-related IRRGs. Then, we identified that OS- and EFS-related IRRG signatures and found that the OS and EFS of NB patients in the low-risk group were significantly superior than those in the high-risk group (both P value < 0.0001). The AUC values of 3-, 5-, and 7-year OS are 0.910, 0.933, and 0.921, respectively, and 3-, 5-, and 7-year EFS are 0.840, 0.835, and 0.837, respectively. In addition, we found that both IRRG signatures can be used as independent prognostic indicators for patients with NB. Both IRRG signatures still have good predictive ability in validation cohort.

Conclusions: We constructed and validated two prognostic gene signatures based on IRRGs. Our study helped us to better understand the role of inflammation in NB and provided new insights for the prognosis assessment and treatment strategy for NB patients.

PubMed Disclaimer

Conflict of interest statement

All authors declare that the research was conducted in the absence of any competing interest.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Figure 5
Figure 5
Figure 6
Figure 6
Figure 7
Figure 7
Figure 8
Figure 8
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ward E., DeSantis C., Robbins A., Kohler B., Jemal A. Childhood and adolescent cancer statistics, 2014. CA: a Cancer Journal for Clinicians . 2014;64(2):83–103. doi: 10.3322/caac.21219. - DOI - PubMed
    1. Brodeur G. M. Neuroblastoma: biological insights into a clinical enigma. Nature Reviews Cancer . 2003;3(3):203–216. doi: 10.1038/nrc1014. - DOI - PubMed
    1. Pearson A. D., Pinkerton C. R., Lewis I. J., et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. The Lancet Oncology . 2008;9(3):247–256. doi: 10.1016/S1470-2045(08)70069-X. - DOI - PubMed
    1. Ladenstein R., Pötschger U., Pearson A. D. J., et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high- dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet Oncology . 2017;18(4):500–514. doi: 10.1016/S1470-2045(17)30070-0. - DOI - PubMed
    1. Matthay K. K., Reynolds C. P., Seeger R. C., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. Journal of Clinical Oncology . 2009;27(7):1007–1013. doi: 10.1200/JCO.2007.13.8925. - DOI - PMC - PubMed

LinkOut - more resources